The New England Journal of Medicine recently published a paper that showed “dramatic and rapid” regression of glioblastoma in three patients who received groundbreaking CAR-T therapy. The clinical trial was conducted at a lab within Mass General Cancer Center that received earlier funding from Swim Across America – Boston and Swim Across America – Nantucket.
Preliminary findings from the clinical trial are hopeful and show the promise of cell therapy for treating incurable conditions.
“The CAR-T platform has revolutionized how we think about treating patients with cancer, but solid tumors like glioblastoma have remained challenging to treat because not all cancer cells are exactly alike and cells within the tumor vary. Our approach combines two forms of therapy, allowing us to treat glioblastoma in a broader, potentially more effective way.” said Bryan Choi, MD, PhD, neurosurgeon and associate director of the Center for Brain Tumor Immunology and Immunotherapy, Cellular Immunotherapy Program, Mass General Cancer Center and Department of Neurosurgery.
Days after a single treatment, the three patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression.
MRI scans conducted before and after treatment showed initial regression in tumor size. In time, the researchers observed tumor progression in these patients, but given the strategy’s promising preliminary results, the team will pursue strategies to extend the durability of response.
Dr. Choi expressed gratitude for the Swim Across America – Boston grant that made this research possible. Dr. Choi’s lab also receives funding from Swim Across America – Nantucket.
“Swim Across America directly supports my laboratory, which is dedicated to developing novel experimental immune therapies for patients with brain cancer. SAA funded a critical step in the early stage of discovery, allowing us to take on high risk projects that otherwise might not be possible.” said Dr. Choi.
“Without this type of support, my lab would not be able to develop or advance new therapies toward clinical studies like the one published here.”
Swim Across America – Boston and Swim Across America – Nantucket leadership teams visited Dr. Choi at Mass General Cancer Center in March 2023, just one month before the clinical trial was launched. During the visit, SAA leaders were treated to an informative presentation and lab tour from Dr. Choi.
During the tour, Janel Jorgensen McArdle, Chief Operating Officer of Swim Across America, pointed out that Dr. Choi’s research falls in the “sweet spot” of the high risk, high reward research that Swim Across America is pursuing.
“This promising research aligns perfectly with the opportunities that Swim Across America seeks to support. We are excited that SAA funding could help accelerate (this research) to patient trials.”
Swim Across America’s grant agreement with beneficiaries, such as Mass General Cancer Center, requires that 100% of an SAA grant must be spent on approved research and clinical trial programs. Since 1987, SAA has granted over $100M to innovative and otherwise unfunded ideas so that the time of oncologists is protected to make progress and develop new treatments.
Swim Across America 